Regeneron Q1 revenue beats estimates on EYLEA HD sales

Regeneron Pharmaceuticals

29/04/2026 11:41

Overview

U.S. biotechnology firm's Q1 revenue rose 19%, beating analyst expectations

Adjusted EPS for Q1 rose 15%, beating analyst expectations

Company authorized new $3.0 bln share repurchase program

Outlook

Regeneron lowered 2026 GAAP gross margin guidance on net product sales to 77%-78% from 79%-80%

Company raised 2026 GAAP COCM guidance to $955 mln–$1.035 bln from $940 mln–$1.020 bln

Regeneron expects production at Limerick facility to normalize by end of Q2 2026

Result Drivers

EYLEA HD DEMAND - EYLEA HD U.S. net product sales rose 52% on higher demand, partly offset by lower net selling price and inventory levels

EYLEA FRANCHISE PRESSURE - Total EYLEA HD and EYLEA U.S. net sales fell 10% as EYLEA faced competitive pressures and patient transitions to EYLEA HD

Company press release: ID:nGNX1DBr6

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$3.61 bln
$3.49 bln (21 Analysts)
Q1 Adjusted EPS
Beat
$9.47
$8.94 (24 Analysts)
Q1 EPS
$6.75


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 25 "strong buy" or "buy", 7 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Regeneron Pharmaceuticals Inc is $875.00, about 19.6% above its April 28 closing price of $731.77

The stock recently traded at 15 times the next 12-month earnings vs. a P/E of 17 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)